LAG3 and non-small cell lung carcinoma: Although there are active clinical trials of LAG-3-targeting therapeutics for NSCLC (NCT03625323, NCT01968109, NCT02750514, NCT02460224, and NCT03538028), it is still unknown how its expression is related to clinicopathologic factors and how it affects NSCLC prognosis.